We launched a Phase 1 trial in July 2015 in the United Kingdom of 72 chronically infected HBV patients with controlled disease under standard of care. The primary objective of the trial is to assess the safety and tolerability of HepTcell. As a secondary objective, the trial will also measure the immune response induced by HepTcell following administration.作者: lwkais 时间: 2016-6-4 23:27
